Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-11-03 00:00:00 ET · period of report 2022-11-01 · accession 0000899243-22-034883 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-11-03 | 2022-11-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $312.64 | -320 | 38.2K | -0.8% | -$100.0K |
| 2022-11-03 | 2022-11-01 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $312.84 | -768 | 38.4K | -2% | -$240.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-02 | S | D | 56 | $310.10 | 38,368 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $310.10 (range $309.50 to $310.48). |
| 2 | Common | Common Stock | 2022-11-02 | S | D | 10 | $315.68 | 38,126 | D | — | — | |
| 3 | Common | Common Stock | 2022-11-02 | S | D | 12 | $314.43 | 38,136 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F7) Open market sales reported on this line occurred at a weighted average price of $314.43 (range $314.42 to $314.48). |
| 4 | Common | Common Stock | 2022-11-02 | S | D | 81 | $313.37 | 38,148 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F6) Open market sales reported on this line occurred at a weighted average price of $313.37 (range $312.98 to $313.97). |
| 5 | Common | Common Stock | 2022-11-01 | F | D | 768 | $312.84 | 38,424 | D | — | — | |
| 6 | Common | Common Stock | 2022-11-02 | S | D | 22 | $317.77 | 38,104 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F8) Open market sales reported on this line occurred at a weighted average price of $317.77 (range $317.56 to $317.82). |
| 7 | Common | Common Stock | 2022-11-02 | S | D | 39 | $311.17 | 38,329 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $311.17 (range $310.51 to $311.45). |
| 8 | Common | Common Stock | 2022-11-02 | S | D | 100 | $312.40 | 38,229 | D | — | — | (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $312.40 (range $311.98 to $312.90). |